RNAC (Cartesian Therapeutics) Shiller PE Ratio: (As of Sep. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RNAC Cartesian Therapeutics Inc RNAC
28 GF Score
Price $8.43
GF Value $0.28
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Cartesian Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cartesian Therapeutics  (NAS:RNAC) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cartesian Therapeutics Shiller PE Ratio Related Terms


Cartesian Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Cartesian Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cartesian Therapeutics Shiller PE Ratio Chart

Cartesian Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cartesian Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RNAC vs FATE, FULC, BCYC: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Cartesian Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cartesian Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cartesian Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cartesian Therapeutics's Shiller PE Ratio falls into.


RNAC
28GF Score
Cartesian Therapeutics Inc RNAC
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cartesian Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cartesian Therapeutics's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Cartesian Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.46/333.9520*333.9520
=0.460

Current CPI (Jun. 2026) = 333.9520.

Cartesian Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -12.900 241.428 -17.844
201612 -23.100 241.432 -31.952
201703 -24.600 243.801 -33.696
201706 -25.500 244.955 -34.765
201709 -19.800 246.819 -26.790
201712 -26.400 246.524 -35.763
201803 -21.300 249.554 -28.504
201806 -25.200 251.989 -33.397
201809 -21.300 252.439 -28.178
201812 -19.500 251.233 -25.920
201903 -9.300 254.202 -12.218
201906 -11.100 256.143 -14.472
201909 -7.800 256.759 -10.145
201912 -8.400 256.974 -10.916
202003 -6.300 258.115 -8.151
202006 -7.500 257.797 -9.716
202009 -2.700 260.280 -3.464
202012 -4.200 260.474 -5.385
202103 -6.600 264.877 -8.321
202106 -0.063 271.696 -0.077
202109 -4.800 274.310 -5.844
202112 0.900 278.802 1.078
202203 2.400 287.504 2.788
202206 1.800 296.311 2.029
202209 -1.500 296.808 -1.688
202212 -1.500 296.797 -1.688
202303 -4.240 301.836 -4.691
202306 -2.230 305.109 -2.441
202309 -1.740 307.789 -1.888
202312 -41.560 306.746 -45.246
202403 -10.500 312.332 -11.227
202406 0.540 314.175 0.574
202409 -1.130 315.301 -1.197
202412 0.120 315.605 0.127
202503 -0.680 319.799 -0.710
202506 0.500 322.561 0.518
202509 -1.380 324.800 -1.419
202512 -3.570 324.054 -3.679
202603 -1.460 330.213 -1.477
202606 0.460 333.952 0.460

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Cartesian Therapeutics (RNAC) Overvalued in 2026?

Based on GuruFocus' analysis, Cartesian Therapeutics stock appears to be overvalued. The current stock price of $8.43 is trading 2910.7% above its estimated GF Value™ of $0.28. GuruFocus considers Cartesian Therapeutics to be Significantly Overvalued.

Key valuation signals for RNAC:

  • Shiller PE Ratio:
  • GF Value™: $0.28 vs. price of $8.43 (2910.7% above fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the RNAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cartesian Therapeutics Business Description

Other Exchanges 1S70:Germany
Address 7495 New Horizon Way, Frederick, MD, USA, 21703
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
28GF Score

Get the complete analysis for RNAC

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.43
Price
$0.28
GF Value